BCG As Defense Against SARS Study (H-47454)
Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2. A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses.
SARS-CoV-2 infection is a contagious virus affecting everyone at this time. The virus affects the nose, throat and sometimes the lungs. There is no current vaccination or treatment against this virus. Researchers at the Baylor College of Medicine (also working with Texas A&M University, MD Anderson Cancer Center and Cedars Sinai Medical Center) are looking for healthcare worker volunteers to participate in a study evaluating the use of the Bacillus Calmette Guérin (BCG) vaccine to see if it improves health care workers immune response and lessens illness severity from coronavirus. Consent will be collected electronically and by phone so we can adhere with current social distancing practices. You receive a one time vaccination and will have to submit daily diary entries on an electronic device (e.g. Smart phone or tablet) through a secure research "app" or web portal. Blood samples and stool samples will also be collected at designated timepoints.
• You may be eligible if you are:
• Between the ages of 18 and 74
• Able to use an app to provide data electronically in order to adhere with current social distancing practices
• Able to participate for 6 months
Benefits of participating include: subjects randomized to the BCG-arm may experience prevention SARS-CoV-2 infection and/or lower risk on developing severe illness caused by SARS-CoV-2.